OBJECTIVES: CD38 participates in lymphocyte ontogeny and function and may be involved in autoimmunity. Absence of CD38 accelerates development of non-obese diabetic (NOD) mice diabetes and anti-CD38 antibodies are good markers of human disease. Little is known regarding systemic autoimmunity. Active SLE patients have higher numbers of CD38(+) T and B cells. CD38 is a candidate gene for the murine Lmb2 lupus locus. We aimed to investigate whether CD38 was involved in lupus development. METHODS: We developed Cd38(-/-)-Fas(lpr)/Fas(lpr) mice and monitored them for development of a lupus-like disease through measurement of protein excretion in urine, histological assessment of the kidneys, quantification of circulating immunoglobulins and autoantibodies. We have also immunophenotyped 2- and 6-month old Cd38(-/-)-Fas(lpr)/Fas(lpr) mice. RESULTS: We found that absence of CD38 accelerated disease development: female Cd38(-/-)-Fas(lpr)/Fas(lpr) mice presented severe proteinuria, GN, deposition of ICs in the renal medulla and increased amounts of circulating immunoglobulin G (IgG), although anti-dsDNA autoantibodies and RF were not significantly increased at disease onset. We have found that Cd38(-/-)-Fas(lpr)/Fas(lpr) male mice, similarly to other murine models of lupus, were able to control disease. Absence of CD38 in lpr mice altered differentiation of T cells and dendritic cells (DC). CONCLUSION: Although the role of CD38 in tolerance is still to be elucidated, we provide evidence that it may play an active role in the control of a murine lupus-like disease.
OBJECTIVES:CD38 participates in lymphocyte ontogeny and function and may be involved in autoimmunity. Absence of CD38 accelerates development of non-obese diabetic (NOD) micediabetes and anti-CD38 antibodies are good markers of human disease. Little is known regarding systemic autoimmunity. Active SLEpatients have higher numbers of CD38(+) T and B cells. CD38 is a candidate gene for the murineLmb2 lupus locus. We aimed to investigate whether CD38 was involved in lupus development. METHODS: We developed Cd38(-/-)-Fas(lpr)/Fas(lpr) mice and monitored them for development of a lupus-like disease through measurement of protein excretion in urine, histological assessment of the kidneys, quantification of circulating immunoglobulins and autoantibodies. We have also immunophenotyped 2- and 6-month old Cd38(-/-)-Fas(lpr)/Fas(lpr) mice. RESULTS: We found that absence of CD38 accelerated disease development: female Cd38(-/-)-Fas(lpr)/Fas(lpr) mice presented severe proteinuria, GN, deposition of ICs in the renal medulla and increased amounts of circulating immunoglobulin G (IgG), although anti-dsDNA autoantibodies and RF were not significantly increased at disease onset. We have found that Cd38(-/-)-Fas(lpr)/Fas(lpr) male mice, similarly to other murine models of lupus, were able to control disease. Absence of CD38 in lpr mice altered differentiation of T cells and dendritic cells (DC). CONCLUSION: Although the role of CD38 in tolerance is still to be elucidated, we provide evidence that it may play an active role in the control of a murinelupus-like disease.
Authors: Ana Henriques; Isabel Silva; Luís Inês; M Margarida Souto-Carneiro; M Luísa Pais; Hélder Trindade; José António Pereira da Silva; Artur Paiva Journal: Clin Exp Med Date: 2015-04-18 Impact factor: 3.984
Authors: Julianna D Zeidler; Kelly A Hogan; Guillermo Agorrody; Thais R Peclat; Sonu Kashyap; Karina S Kanamori; Lilian Sales Gomez; Delaram Z Mazdeh; Gina M Warner; Katie L Thompson; Claudia C S Chini; Eduardo Nunes Chini Journal: Am J Physiol Cell Physiol Date: 2022-02-09 Impact factor: 4.249
Authors: Colton J Garelli; Maggi Ahmed Refat; Padma P Nanaware; Zaida G Ramirez-Ortiz; Mehdi Rashighi; Jillian M Richmond Journal: Front Immunol Date: 2020-07-02 Impact factor: 7.561
Authors: Eri Katsuyama; Abel Suarez-Fueyo; Sean J Bradley; Masayuki Mizui; Ana V Marin; Lama Mulki; Suzanne Krishfield; Fabio Malavasi; Joon Yoon; Shannan J Ho Sui; Vasileios C Kyttaris; George C Tsokos Journal: Cell Rep Date: 2020-01-07 Impact factor: 9.423
Authors: Stephanie A Amici; Nicholas A Young; Janiret Narvaez-Miranda; Kyle A Jablonski; Jesus Arcos; Lucia Rosas; Tracey L Papenfuss; Jordi B Torrelles; Wael N Jarjour; Mireia Guerau-de-Arellano Journal: Front Immunol Date: 2018-07-10 Impact factor: 7.561
Authors: África Martínez-Blanco; Marilú Domínguez-Pantoja; María Botía-Sánchez; Sonia Pérez-Cabrera; Nerea Bello-Iglesias; Paula Carrillo-Rodríguez; Natividad Martin-Morales; Antonio Lario-Simón; María M Pérez-Sánchez-Cañete; Laura Montosa-Hidalgo; Salvador Guerrero-Fernández; Victoria M Longobardo-Polanco; Sandra Redondo-Sánchez; Alberto Cornet-Gomez; María Torres-Sáez; Ana Fernández-Ibáñez; Laura Terrón-Camero; Eduardo Andrés-León; Francisco O'Valle; Ramón Merino; Mercedes Zubiaur; Jaime Sancho Journal: Front Immunol Date: 2021-08-24 Impact factor: 7.561